PAI-1 Validations

• Validation includes a comparison of multiplex assays to our in-house PAI-1 antigen ELISA

• Assays are not always “harmonized” with respect to standardization. Slope(m) values reflect degree of harmonization
Suppliers

• A: Bio-Rad
• B: Linco Research (done)
• C: Upstate
• D: Biosource
• E: RnD Systems
Supplier B

Adipokine Panel A

Supplier B total PAI-1 vs LCBR PAI-1 ag ELISA:
Citrate Set n=24

\[ y = 1.6524x + 0.8972 \]
\[ R^2 = 0.5282 \]

Total PAI-1

Mean replicate CV=9.6%
\( R^2 = 0.53 \)
Slope(m)=1.65
Supplier B

Adipokine Panel A

Active PAI-1

Mean replicate CV
= 25.5%
R² = 0.60
Slope(m) = 0.39

LCBR PAI-1 ag vs Supplier B Active PAI-1: Citrate Set
n=24

y = 0.3873x - 1.538
R² = 0.6034
Supplier B Human Sepsis/Apoptosis vs Adipokine Panel A total PAI-1: 8-16-04 Serum Set

\[ y = 0.7098x + 277.44 \]
\[ R^2 = 0.8883 \]

Total PAI-1 levels assayed using a kit to measure Adiponectin, Resistin and total PAI-1, agreed well with levels obtained using a kit to measure MIF and total PAI-1.

\[ R^2 = 0.89 \]
\[ \text{Slope}(m) = 0.71 \]